Novo Nordisk stock has surged thanks to booming sales of Ozempic and Wegovy.One of the biggest narratives in the pharmaceutical space right now is that of weight-loss treatments.Glucagon-like peptide 1 (GLP-1) agonists such as Ozempic and Wegovy are making significant headway among diabetes and obesity care patients. Both turned out to be blockbuster drugs, and are made by Danish pharmaceutical powerhouse Novo Nordisk (NVO 3.27%).Investors have cheered Novo as the company continues dominating the fast-growi ...